循环肿瘤 DNA 生物标志物在前列腺癌反应评估中的应用。
Circulating Tumor DNA Biomarkers for Response Assessment in Prostate Cancer.
机构信息
Department of Medical Oncology, Mayo Clinic, Rochester, Minnesota.
出版信息
Clin Cancer Res. 2023 Aug 1;29(15):2745-2747. doi: 10.1158/1078-0432.CCR-23-1043.
Abstract
Circulating tumor DNA (ctDNA) is measurable in the majority of metastatic castration-resistant prostate cancer patients. Data indicate that ctDNA present at baseline can serve as a prognostic biomarker and changes in the ctDNA posttreatment can rapidly predict both time to progression and survival. See related article by Tolmeijer et al., p. 2835.
摘要
循环肿瘤 DNA（ctDNA）在大多数转移性去势抵抗性前列腺癌患者中可测量。数据表明，基线时存在的 ctDNA 可用作预后生物标志物，并且治疗后 ctDNA 的变化可快速预测进展时间和生存。参见 Tolmeijer 等人的相关文章，第 2835 页。
相似文献
1
Circulating Tumor DNA Biomarkers for Response Assessment in Prostate Cancer.循环肿瘤 DNA 生物标志物在前列腺癌反应评估中的应用。
Clin Cancer Res. 2023 Aug 1;29(15):2745-2747. doi: 10.1158/1078-0432.CCR-23-1043.
2
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.基于循环肿瘤 DNA 改变的临床和基因组分析在转移性激素敏感型和去势抵抗性前列腺癌中的应用。
EBioMedicine. 2020 Apr;54:102728. doi: 10.1016/j.ebiom.2020.102728.
3
Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.循环肿瘤 DNA 作为阿比特龙治疗后转移性去势抵抗性前列腺癌恩扎卢胺治疗反应的预测因子。
Cancer Treat Res Commun. 2020;24:100193. doi: 10.1016/j.ctarc.2020.100193. Epub 2020 Jul 14.
4
Using early on-treatment circulating tumor DNA measurements as response assessment in metastatic castration resistant prostate cancer.将早期治疗期间循环肿瘤DNA检测结果用作转移性去势抵抗性前列腺癌的疗效评估指标
Oncotarget. 2024 Jul 2;15:421-423. doi: 10.18632/oncotarget.28599.
5
Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.对 3334 例晚期前列腺癌患者循环肿瘤 DNA 的基因组分析鉴定出可靶向的 BRCA 改变和 AR 耐药机制。
Clin Cancer Res. 2021 Jun 1;27(11):3094-3105. doi: 10.1158/1078-0432.CCR-20-4805. Epub 2021 Feb 8.
6
Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer.转移性去势抵抗性前列腺癌患者的循环肿瘤 DNA 改变。
Cancer. 2019 May 1;125(9):1459-1469. doi: 10.1002/cncr.31959. Epub 2019 Jan 8.
7
Analysis of the Prognostic Significance of Circulating Tumor DNA in Metastatic Castrate Resistant Prostate Cancer.循环肿瘤 DNA 分析在转移性去势抵抗性前列腺癌中的预后意义。
Clin Genitourin Cancer. 2021 Dec;19(6):564.e1-564.e10. doi: 10.1016/j.clgc.2021.07.012. Epub 2021 Jul 31.
8
Genomic mutation profiling using liquid biopsy in Korean patients with prostate cancer: Circulating tumor DNA mutation predicts the development of castration resistance.韩国前列腺癌患者液体活检的基因组突变分析：循环肿瘤 DNA 突变可预测去势抵抗的发生。
Investig Clin Urol. 2021 Mar;62(2):224-232. doi: 10.4111/icu.20200406.
9
TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.循环肿瘤 DNA 中 TP53 功能获得性突变与转移性去势抵抗性前列腺癌男性患者
Clin Genitourin Cancer. 2020 Apr;18(2):148-154. doi: 10.1016/j.clgc.2019.10.022. Epub 2019 Nov 6.
10
Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.前列腺癌中循环肿瘤DNA与配对转移组织活检的一致性
J Natl Cancer Inst. 2017 Dec 1;109(12). doi: 10.1093/jnci/djx118.
引用本文的文献
1
Synergizing Liquid Biopsy and Hybrid PET Imaging for Prognostic Assessment in Prostate Cancer: A Focus Review.液体活检与混合正电子发射断层扫描成像协同用于前列腺癌预后评估：聚焦综述
Biomolecules. 2025 Jul 18;15(7):1041. doi: 10.3390/biom15071041.
2
Deferral of systemic therapy in patients with oligorecurrent prostate cancer treated with metastasis-directed radiotherapy.接受转移灶定向放疗的寡转移复发性前列腺癌患者全身治疗的延迟
Ann Transl Med. 2025 Jun 27;13(3):29. doi: 10.21037/atm-24-187. Epub 2025 Jun 24.
3
Advance in prostate cancer biomarker discovery: bridging detection, prognosis and therapeutics.前列腺癌生物标志物发现的进展：连接检测、预后与治疗
Discov Oncol. 2025 May 30;16(1):954. doi: 10.1007/s12672-025-02763-1.
4
Precision Targeting in Metastatic Prostate Cancer: Molecular Insights to Therapeutic Frontiers.转移性前列腺癌的精准靶向治疗：治疗前沿的分子见解
Biomolecules. 2025 Apr 27;15(5):625. doi: 10.3390/biom15050625.
5
A revolutionary era in advancing precision immuno-oncology; role of circulating tumor cells.推进精准免疫肿瘤学的一个变革性时代；循环肿瘤细胞的作用。
J Liq Biopsy. 2024 Oct 11;6:100169. doi: 10.1016/j.jlb.2024.100169. eCollection 2024 Dec.
6
Health Economic Evaluations of Circulating Tumor DNA Testing for Cancer Screening: Systematic Review.用于癌症筛查的循环肿瘤DNA检测的卫生经济学评估：系统评价
Cancer Med. 2025 Feb;14(3):e70641. doi: 10.1002/cam4.70641.
7
Prevalence and Prognostic Implications of PSA Flares during Radium-223 Treatment among Men with Metastatic Castration Resistant Prostate Cancer.镭-223治疗期间转移性去势抵抗性前列腺癌男性患者中前列腺特异性抗原（PSA）波动的患病率及其预后意义
J Clin Med. 2023 Aug 28;12(17):5604. doi: 10.3390/jcm12175604.
本文引用的文献
1
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer.早期治疗中循环肿瘤 DNA 分数的变化与转移性去势抵抗性前列腺癌对恩杂鲁胺或阿比特龙的反应
Clin Cancer Res. 2023 Aug 1;29(15):2835-2844. doi: 10.1158/1078-0432.CCR-22-2998.
2
Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing Lu-PSMA-I&T Therapy.（剂量 2）6 周时 Lu-PSMA SPECT 定量预测 Lu-PSMA-I&T 治疗患者的短期无进展生存期。
J Nucl Med. 2023 Mar;64(3):410-415. doi: 10.2967/jnumed.122.264677. Epub 2022 Sep 8.
3
[F]-Labeled PARP-1 PET imaging of PSMA targeted alpha particle radiotherapy response.[F]-标记的 PARP-1 PET 成像用于 PSMA 靶向 α 粒子放射治疗反应的评估。
Sci Rep. 2022 Jul 29;12(1):13034. doi: 10.1038/s41598-022-17460-0.
4
Identification of tumor tissue-derived DNA methylation biomarkers for the detection and therapy response evaluation of metastatic castration resistant prostate cancer in liquid biopsies.鉴定肿瘤组织来源的DNA甲基化生物标志物用于液体活检中转移性去势抵抗性前列腺癌的检测及治疗反应评估
Mol Cancer. 2022 Jan 3;21(1):7. doi: 10.1186/s12943-021-01445-0.
5
Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research.细胞外囊泡作为液体活检中前列腺癌生物标志物的来源：十年研究
Br J Cancer. 2022 Feb;126(3):331-350. doi: 10.1038/s41416-021-01610-8. Epub 2021 Nov 22.
6
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer.镥 177-PSMA-617 治疗转移性去势抵抗性前列腺癌。
N Engl J Med. 2021 Sep 16;385(12):1091-1103. doi: 10.1056/NEJMoa2107322. Epub 2021 Jun 23.
7
Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA.通过对循环肿瘤 DNA 进行低深度全基因组测序来阐明治疗过程中的前列腺癌行为。
Eur Urol. 2021 Aug;80(2):243-253. doi: 10.1016/j.eururo.2021.05.030. Epub 2021 Jun 5.
8
Value of Early Circulating Tumor Cells Dynamics to Estimate Docetaxel Benefit in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients.早期循环肿瘤细胞动态变化对评估多西他赛在转移性去势抵抗性前列腺癌（mCRPC）患者中的获益价值
Cancers (Basel). 2021 May 12;13(10):2334. doi: 10.3390/cancers13102334.
9
In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2 Cycle Is Better Predictor of Overall Survival of Prostate Cancer Patients Treated With Lu-PSMA.与前列腺特异性抗原（PSA）相比，基于改良实体瘤疗效评价标准（RECIST）1.1在2个周期后进行的中期镓-68-前列腺特异性膜抗原（PSMA）正电子发射断层扫描（PET）/计算机断层扫描（CT）反应评估，能更好地预测接受镥-PSMA治疗的前列腺癌患者的总生存期。
Front Oncol. 2021 Mar 17;11:578093. doi: 10.3389/fonc.2021.578093. eCollection 2021.
10
Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial.多中心国际试验的生物标志物分析：转移性去势抵抗性前列腺癌患者使用醋酸阿比特龙治疗一个周期后的血浆肿瘤基因转化。
Ann Oncol. 2021 Jun;32(6):726-735. doi: 10.1016/j.annonc.2021.03.196. Epub 2021 Mar 29.
Zotero 插件